Table 1.
Patient demographics and tumour characteristics
| All centres | Centre 1 | Centre 2 | Centre 3 | Centre 4 | |
|---|---|---|---|---|---|
| Gender | N patients (%) | ||||
| Female | 171 (98.3%) | 37 (100.0%) | 19 (95.0%) | 92 (97.9%) | 23 (100.0%) |
| Male | 2 (1.1%) | 0 (0%) | 1 (5.0%) | 1 (1.1%) | 0 (0%) |
| Unknown | 1 (0.6%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
| Age at surgery (years) | Median (range) | ||||
| Age at surgery (years) | 53 (24–78) | 49 (33–74) | 51 (37–72) | 56 (24–78) | 54 (38–74) |
| Unknown (N patients (%)) | 1 (0.6%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
| Menopausal status | N patients (%) | ||||
| Pre-menopausal | 81 (46.6%) | 24 (64.9%) | 8 (40.0%) | 38 (40.4%) | 11 (47.8%) |
| Post-menopausal | 86 (49.4%) | 13 (35.1%) | 10 (50.0%) | 51 (54.3%) | 12 (52.2%) |
| Peri-menopausal | 2 (1.1%) | 0 (0%) | 1 (5.0%) | 1 (1.1%) | 0 (0%) |
| Not applicable (male) | 2 (1.1%) | 0 (0%) | 1 (5.0%) | 1 (1.1%) | 0 (0%) |
| Unknown | 3 (1.7%) | 0 (0%) | 0 (0%) | 3 (3.2%) | 0 (0%) |
| Number of involved nodes | N patients (%) | ||||
| N = 0 | 165 (94.8%) | 35 (94.6%) | 20 (100.0%) | 88 (93.6%) | 22 (95.6%) |
| N ≥ 1 | 1 (0.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.3%) |
| Micro-metastasis | 7 (4.0%) | 2 (5.4%) | 0 (0%) | 5 (5.3%) | 0 (0%) |
| Unknown | 1 (0.6%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
| Tumour diameter (mm) | Median (range) | ||||
| Tumour diameter | 23 (6–120) | 18 (6–70) | 25.5 (9–42) | 25 (10–120) | 20 (6–56) |
| N cases (%) | |||||
| < 10 mm | 6 (3.4%) | 3 (8.1%) | 1 (5.0%) | 0 (0%) | 2 (8.7%) |
| 10–19 | 46 (26.0%) | 20 (54.1%) | 4 (20.0%) | 16 (17.0%) | 6 (26.1%) |
| 20–29 | 62 (35.0%) | 9 (24.3%) | 8 (40.0%) | 34 (36.2%) | 11 (47.8%) |
| 30–39 | 27 (15.3%) | 2 (5.4%) | 6 (30.0%) | 16 (17.0%) | 3 (13.0%) |
| 40–49 | 17 (9.6%) | 3 (8.1%) | 1 (5.0%) | 12 (12.8%) | 1 (4.3%) |
| ≥ 50 | 18 (10.2%) | 2 (5.4%) | 0 (0%) | 15 (16.0%) | 1 (4.3%) |
| Unknown | 1 (0.6%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
| Tumour grade | Median (range) | ||||
| Tumour grade | 2 (1–3) | 2 (2–3) | 2 (2–3) | 2 (1–3) | 2 (2–3) |
| N cases (%) | |||||
| Grade 1 | 2 (1.1%) | 0 (0%) | 0 (0%) | 2 (2.1%) | 0 (0%) |
| Grade 2 | 103 (58.2%) | 23 (59.0%) | 11 (55.0%) | 53 (56.4%) | 15 (65.2%) |
| Grade 3 | 71 (40.1%) | 16 (41.0%) | 9 (45.0%) | 38 (40.4%) | 8 (22.7%) |
| Unknown | 1 (0.6%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
| Prognostic indices | Median (range) | ||||
| NPI | 4.0 (2.4–5.4) | 3.8 (3.1–4.9) | 3.7 (3.4–4.8) | 4.1 (2.4–5.4) | 3.7 (3.1–4.7) |
| RS% | 11% (3–34%) | 11% (4–34%) | 10% (3–30%) | 11% (3–34%) | 9% (5–23%) |
| RSPC | 15% (4–63%) | 14% (4–63%) | 14% (5–33%) | 18% (5–51%) | 13 (6–31%) |
Percentages indicate the proportions of patients for age, menopausal status and number of involved nodes; for tumour size and grade percentages they are the proportions of cases. NPI, RS% and RSPC distributions for the whole study and for each centre individually are also given